The Australian Life Saving Drugs Program and its implications for medical assistance system for the rare diseases in China
10.3969/j.issn.1674-2982.2015.08.010
- VernacularTitle:澳大利亚救生药物计划及对我国罕见病医疗救助制度的启示
- Author:
Yiru GUAN
;
Wei XIANG
;
Fang ZHANG
- Publication Type:Journal Article
- Keywords:
Australian Life Saving Drugs Program;
Rare disease;
Orphan drug;
Medical security
- From:
Chinese Journal of Health Policy
2015;(8):51-55
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To introduce the Australian Life Saving Drugs Program ( LSDP) and provide references for medical assistance system for the rare diseases in China. Methods:The main content and characteristics of LSDP were analyzed and compared with the Chinese status quo valuation. Results:Through the orphan drug designation and cost-effectiveness evaluation, eligible drugs are included in LSDP and funded to the rare disease patients. LSDP stip-ulated the strict funding criteria and conditions, established the Guidelines and Disease Advisory Committees, and processed the post-market reviews program in order to guarantee the medication requirements of the patients. Conclu-sions:The Australian experience is worth learning and China should implement a country-led management system for the rare disease and orphan drugs, and explore a medical assisstance system in line with the Chinese national condi-tion based on the catastrophic medical insurances.
